Table 3 Characterization of minor H... | American Society of Hematology

Table 3

Characterization of minor H antigen–specific CTL clones derived by primary in vitro stimulation

CTL clone	HLA-restricting allele	Frequency of minor H antigen phenotype, percentage	Clonal expansion more than 12 days, log10	Interferon-γ secretion after stimulation with B-LCL, pg/mL		Cytotoxicity versus B-LCL, percentage (ET 20:1)		Cytotoxicity versus fibroblasts, percentage (ET 20:1): recipient
CTL clone	HLA-restricting allele	Frequency of minor H antigen phenotype, percentage	Clonal expansion more than 12 days, log10	Recipient	Donor	Recipient	Donor
J 47	B0801	50	3.01	600	< 50	76	0	3
J 7	B0801	30	2.95	100	< 50	77	0	6
L 3.2	B7	28	2.94	> 5000	< 50	40	0	0
L 17.4	A0201	35	3.01	450	< 50	59	0	0
R 7	B35/C0401	30	2.90	200	< 50	95	0	1
R 29	B4402,4403	45	2.96	750	< 50	100	0	1
K 9.3	B0702	52	3.09	> 5000	< 50	91	0	12
I 19.2	A2406	56	2.87	1100	< 50	70	0	0
M 56	A0201	50	2.93	150	< 50	64	1	8
M 37.6	B2705	40	2.94	100	< 50	74	0	0

CTL clone	HLA-restricting allele	Frequency of minor H antigen phenotype, percentage	Clonal expansion more than 12 days, log10	Interferon-γ secretion after stimulation with B-LCL, pg/mL		Cytotoxicity versus B-LCL, percentage (ET 20:1)		Cytotoxicity versus fibroblasts, percentage (ET 20:1): recipient
CTL clone	HLA-restricting allele	Frequency of minor H antigen phenotype, percentage	Clonal expansion more than 12 days, log10	Recipient	Donor	Recipient	Donor
J 47	B0801	50	3.01	600	< 50	76	0	3
J 7	B0801	30	2.95	100	< 50	77	0	6
L 3.2	B7	28	2.94	> 5000	< 50	40	0	0
L 17.4	A0201	35	3.01	450	< 50	59	0	0
R 7	B35/C0401	30	2.90	200	< 50	95	0	1
R 29	B4402,4403	45	2.96	750	< 50	100	0	1
K 9.3	B0702	52	3.09	> 5000	< 50	91	0	12
I 19.2	A2406	56	2.87	1100	< 50	70	0	0
M 56	A0201	50	2.93	150	< 50	64	1	8
M 37.6	B2705	40	2.94	100	< 50	74	0	0

CTL indicates cytotoxic T lymphocyte; B-LCL, Epstein-Barr virus–transformed lymphoblastoid cell line; and ET, effector-to-target.